EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel RANKL/RANK Inhibitor IMB-R38 Inhibits Osteoporosis Through Regulating Bone Metabolism

Yuyan Zhang, Xinwei Wei, Ren Sheng, Guijun Yang, Xiaowan Han, Jingrui Wang, Chao Liu, Shunwang Li, Lijuan Lei, Weilian Jiang, Yang Lun, Shuyi Si und 2 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262412151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yuyan Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbi…. Hauptthemen laut MEDLINE: RANK Ligand, Osteoporosis, Receptor Activator of Nuclear Factor-kappa B, Benzamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Peking Union Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis is a systemic skeletal disease that severely impairs the health of the elderly population. The interaction between the receptor activator of the NF-κB ligand (RANKL) and its receptor RANK is critical for osteoclast differentiation and function. Therefore, targeting the RANKL/RANK interaction represents a promising strategy for osteoporosis. In this study, we employed a newly established yeast two-hybrid system based on RANKL/RANK interaction and identified IMB-R38, a novel benzamide compound that dose-dependently blocked RANKL/RANK interaction by inhibiting the growth of AH109 cells harboring pAD-RANKL/pBD-RANK plasmids in quadruple-dropout medium. IMB-R38 significantly suppressed osteoclast differentiation, disrupted F-actin ring formation, and downregulated the expression of osteoclast-specific genes, including NFATc1 and MMP9 in RANKL-induced RAW264.7 macrophages. IMB-R38 also promoted osteoblast differentiation by upregulating the expression of osteogenic genes. Importantly, in a dexamethasone (DXM)-induced osteoporotic zebrafish model, IMB-R38 significantly increased bone mineralization, with anti-osteoporosis efficacy superior to that of alendronate sodium (Alen). RT-qPCR assays showed that IMB-R38 significantly upregulated the mRNA expression of osteogenesis genes (Bmp2, Runx2a, Runx2b, Sp7, Alp, and Oc) while markedly downregulating that of the osteoclastogenesis genes (Mmp9, Mmp13, and Mmp2) compared with the DXM group. Mechanistically, an SPR assay confirmed that IMB-R38 directly binds with RANK but not RANKL to disrupt RANKL/RANK interaction. Furthermore, Asp168 of RANK was identified as a key amino acid that mediates both RANKL interaction and IMB-R38 binding. The inhibition of RANKL/RANK by IMB-R38 suppressed JNK phosphorylation and, consequently, osteoclast differentiation and function. Collectively, our findings identify IMB-R38 as a novel RANKL/RANK inhibitor with therapeutic potential for osteoporosis through its regulation of bone metabolism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RANK LigandOsteoporosisReceptor Activator of Nuclear Factor-kappa BBenzamidesBone and BonesAnimalsMiceZebrafishHumansOsteogenesisCell DifferentiationOsteoclastsRAW 264.7 CellsOsteoblastsDisease Models, Animal

Stichwörter der Autor:innen

RANKRANKLRANKL/RANK inhibitorosteoblastosteoclastosteoporosis

Substanzen

RANK LigandReceptor Activator of Nuclear Factor-kappa BBenzamidesTNFSF11 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Acade…

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities, Peking Union Medical College

Zitieren

APA

Zhang, Y., Wei, X., Sheng, R., Yang, G., Han, X., Wang, J., Liu, C., Li, S., Lei, L., Jiang, W., Lun, Y., Si, S., Zhang, J., & Xu, Y. (2025). A Novel RANKL/RANK Inhibitor IMB-R38 Inhibits Osteoporosis Through Regulating Bone Metabolism. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262412151

Vancouver

Zhang Y, Wei X, Sheng R, Yang G, Han X, Wang J, et al. A Novel RANKL/RANK Inhibitor IMB-R38 Inhibits Osteoporosis Through Regulating Bone Metabolism. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262412151

BibTeX
@article{Zhang2025,
  author = {Zhang, Yuyan and Wei, Xinwei and Sheng, Ren and Yang, Guijun and Han, Xiaowan and Wang, Jingrui and Liu, Chao and Li, Shunwang and Lei, Lijuan and Jiang, Weilian and Lun, Yang and Si, Shuyi and Zhang, Jing and Xu, Yanni},
  title = {A Novel RANKL/RANK Inhibitor IMB-R38 Inhibits Osteoporosis Through Regulating Bone Metabolism},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262412151}
}
Kostenlos starten →